Dark Matter Blog

JULY 16, 2021

The only subject in school that held my interest was biology. As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. I wanted to use molecular biology to create drugs. 49 years ago, when I was 16 years old, I wanted to do exactly what I am doing now.

Small Molecule 52

Small Molecule RNA Clinical Trials DNA 52

The Pharma Data

JANUARY 4, 2021

Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. Chimeric PD-1-expressing T-cells engage with the PD-1 ligands on the surface of the cancer cells and this interaction activates the T-cells to directly kill the tumor cells. About Longwood University.

Molecular Biology 40

Molecular Biology Therapies Immune Response Science 40

Codon

APRIL 2, 2024

I was reading a lot of molecular biology papers about different systems, especially circadian clocks, and also a book called Biological Feedback , by Thomas and D’Ari, that sketched out really simple models for different kinds of feedback circuits. So many kinds of people have contributed to biology in different ways.

RNA 55

RNA Engineering Molecular Biology Synthetic Chemistry 55

Codon

FEBRUARY 13, 2024

Such contaminants could have the same toxic effects as the bacterial infection, or provoke a severe immune response in the patient, and therefore the phage mixtures must go through extensive purification and testing procedures. Because frankly, do you know of anything else that can work against multiple drug-resistant bacteria?

Therapies 117

Therapies DNA Virus Clinical Trials 117

Codon

JULY 27, 2023

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. a lower risk of immune responses. You can read all of them here.

Therapies 52

Therapies RNA DNA Engineering 52

Codon

JULY 27, 2023

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. a lower risk of immune responses. You can read all of them here.

Therapies 52

Therapies RNA DNA Engineering 52

Broad Institute

NOVEMBER 20, 2024

Isselbacher Professor of Medicine at Harvard Medical School, director of the Center for Computational and Integrative Biology and member of the Department of Molecular Biology at MGH, and co-director of the Center for Microbiome Informatics and Therapeutics at MIT.

Regulations 84

Regulations Immune Response Molecular Biology Disease 84

Drug Target Review

DECEMBER 12, 2024

Aside from the ethical questions they raise, ESCs are in limited supply and are generally recognised as foreign by the recipient patients immune system. This can trigger an immune response that causes the body to reject these therapeutic cells. Progress in molecular biology and translational science [Internet].

Therapies 59

Therapies DNA Molecular Biology Immune Response 59